1、浙江亚太药业股份有限公司2018 年度财务报表分析报告本报告以亚太药业 2016-2018 年度财务报表数据为分析基础包括资产负债表、利润表、现金流量表和所有者权益变动表水平、垂直分析财务指标盈利能力、偿债能力、营运能力、发展成长能力、杜邦等分析This report is based on the data of financial statements of Listed Companies in 2016-2018.Including horizontal and vertical analysis of SOFP, profit statement, cash flow stateme
2、nt and owners equity statement Financial Indicators Profit, Debt Payment, Operations, Development, DuPont, etc.目 录1 财务报表数据1.1 资产负债表11.2 利润表31.3 现金流量表51.4 所有者权益变动表62 会计报表分析2.1 资产负债表分析72.1.1 水平趋势分析72.1.2 垂直结构分析122.2 利润表分析162.2.1 水平趋势分析162.2.2 垂直结构分析192.3 现金流量表分析222.3.1 水平趋势分析222.3.2 垂直结构分析242.4 所有者权益变
3、动表分析262.4.1 水平趋势分析262.4.2 垂直结构分析263 财务指标分析3.1 偿债能力分析273.1.1 短期偿债能力分析273.1.2 长期偿债能力分析293.2 营运能力分析323.2.1 流动资产周转分析323.2.2 固定资产周转分析343.2.3 总资产周转分析353.3 盈利能力分析353.3.1 资产经营盈利能力分析353.3.2 资本经营盈利能力分析363.3.3 商品经营盈利能力分析383.3.4 盈利质量分析443.4 发展能力分析453.4.1 资产资本成长分析453.4.2 营业收益成长分析463.4.3 每股净资产分析474 杜邦分析4.1 杜邦分析表4
4、84.2 杜邦分析图485 数据来源及计算说明5.1 数据来源505.2 计算说明50浙江亚太药业股份有限公司2018 年度财务报表分析报告1财务报表数据1.1资产负债表表格12016-2018年度 资产负债表项目(万元)Table 1Balance Sheets for 2016-20182016 年2017 年2018 年货币资金81,383.4576,690.6653,449.99应收票据4,676.894,205.582,595.14应收账款27,297.4627,403.9339,771.64预付款项2,637.884,804.276,649.26其他应收款762.31906.891
5、,063.20存货7,898.7411,535.2217,070.02其他流动资产319.15980.604,108.45流动资产合计124,975.89126,527.14124,707.70可供出售金融资产2,606.393,484.163,385.18固定资产24,920.6822,241.1839,751.05在建工程9,207.3137,405.0444,834.51无形资产8,792.018,150.4110,314.37开发支出0.00500.009,812.81商誉67,039.4667,039.4667,039.46长期待摊费用9,142.375,715.767,658.67
6、递延所得税资产385.61463.20623.57其他非流动资产0.002,280.0021,595.40非流动资产合计122,093.84147,279.21205,015.02资产总计247,069.73273,806.35329,722.72短期借款0.004,000.007,500.00应付票据0.003,203.5310,464.61应付账款16,326.1010,917.660.00预收款项3,601.651,588.131,002.74应付职工薪酬731.28813.261,155.38应交税费2,789.082,782.012,554.38应付利息0.005.320.00其他应
7、付款3,988.743,440.383,829.01一年内到期的非流动负债0.000.002,420.00流动负债合计27,436.8526,750.2828,926.1350长期借款0.000.0016,460.00长期应付款0.0010,005.0131,274.32长期负债合计0.0010,005.0147,734.32递延所得税负债71.9838.6523.80递延收益-非流动负债66.5385.19623.04非流动负债合计138.5110,128.8548,381.16负债合计27,575.3636,879.1477,307.28实收资本(或股本)26,824.7253,649.4
8、553,649.45资本公积157,520.34130,695.62130,695.62盈余公积4,300.644,997.576,055.95未分配利润29,504.1246,339.9360,695.18其他综合收益407.90218.99134.87归属于母公司所有者权益合计218,557.72235,901.56251,231.06少数股东权益936.651,025.651,184.37所有者权益合计219,494.37236,927.21252,415.43负债与所有者权益总计247,069.73273,806.35329,722.72浙江亚太药业股份有限公司,简称亚太药业,所属的行
9、业是化学药,公司总部位于浙江省。2018 年,亚太药业的资产总计是 329,722.72 万元,负债合计是 77,307.28 万元,所有者权益合计是 252,415.43 万元。资产构成77,307.28252,415.43负债所有者权益从资产的角度看亚太药业的资产负债表, 2016-2018 年最近三年的资产总计分别是247,069.73 万元、273,806.35 万元、329,722.72 万元,其中, 2018 年的流动资产合计为124,707.70 万元,包括 53,449.99 万元的货币资金和 17,070.02 万元的存货;非流动资产合计为 205,015.02 万元,其中的
10、固定资产占到了 39,751.05 万元。资产总额变动趋势329,722.72273,806.35247,069.732016年2017年2018年350,000.00300,000.00250,000.00200,000.00150,000.00100,000.0050,000.000.00负债方面,亚太药业最近三年的负债总额分别是27,575.36 万元、36,879.14 万元、77,307.28 万元,其中,2018 年的流动负债是 28,926.13 万元,非流动负债是 48,381.16 万元。所有者权益方面, 2016-2018 年亚太药业的所有者权益总额分别为 219,494.
11、37 万元、236,927.21 万元、252,415.43 万元,2018 年的股本为 53,649.45 万元。1.2利润表表格2 2016-2018年度 利润表项目(万元)Table 2 Income Sheets for 2016-20182016 年2017 年2018 年营业总收入86,287.45108,295.11130,970.92营业收入86,287.45108,295.11130,970.92营业总成本72,796.7385,626.23107,912.36营业成本52,308.5660,045.4473,447.30营业税金及附加832.801,000.101,092.
12、44销售费用6,641.6612,808.2315,680.59管理费用9,361.0711,652.6415,116.74财务费用1,984.29-541.171,155.39资产减值损失1,668.36660.981,419.89投资收益33.4934.8840.75其他业务利润0.001,011.991,040.56营业利润13,524.2123,715.7424,139.88营业外收入893.1418.022.80营业外支出28.1518.490.00利润总额14,389.2123,715.2724,142.68所得税费用1,662.183,411.053,205.38净利润12,72
13、7.0320,304.2120,937.30归属于母公司所有者的净利润12,529.0620,215.2120,778.58少数股东损益197.9789.00158.72基本每股收益0.000.000.00稀释每股收益0.000.000.00其他综合收益(损失)-221.62-188.90-84.13综合收益总额12,505.4120,115.3120,853.17归属于母公司所有者的综合收益12,307.4420,026.3120,694.45归属少数股东的综合收益197.9789.00158.722016-2018 年亚太药业的营业总收入分别为 86,287.45 万元、108,295.1
14、1 万元、主要利润表项目140,000.00120,000.00100,000.0080,000.0060,000.0040,000.0020,000.000.00130,970.92 万元,营业总成本分别为 72,796.73 万元、85,626.23 万元、107,912.36 万元, 净利润分别为 12,727.03 万元、20,304.21 万元、20,937.30 万元。2016年2017年2018年营业总收入86,287.45108,295.11130,970.92营业总成本72,796.7385,626.23107,912.36净利润12,727.0320,304.2120,93
15、7.302018 年,亚太药业的营业收入和营业成本分别为 130,970.92 万元、73,447.30 万元,销售费用、管理费用和财务费用分别为 15,680.59 万元、15,116.74 万元和 1,155.39 万元,营业利润和利润总额分别为 24,139.88 万元、24,142.68 万元。1.3现金流量表表格3 2016-2018年度 现金流量表Table 3项目(万元)Cash Flow Sheets for 2016-20182016 年2017 年2018 年销售商品、提供劳务收到的现金73,843.4998,261.91112,321.79收到的税费返还0.00111.3
16、087.49收到的其他与经营活动有关的现金1,408.691,903.442,726.57购买商品、接受劳务支付的现金52,697.7651,562.5569,116.59支付给职工以及为职工支付的现金7,674.568,279.898,733.56支付的各项税费9,764.5810,327.4611,599.44支付其他与经营活动有关的现金8,920.0417,347.3721,986.78经营活动产生的现金流量-3,804.7712,759.363,699.48取得投资收益收到的现金33.4934.8840.75处置长期资产收回的现金60.92287.221,911.35收到的其他与投资活
17、动有关的现金0.0031.410.00购建长期资产支付的现金7,593.9928,273.9063,089.99投资支付的现金1,000.001,100.000.00取得其他营业单位支付的现金1,125.001,125.001,125.00投资活动产生的现金流量-9,624.58-30,145.39-62,262.89取得借款收到的现金4,200.004,000.0026,500.00收到其他与筹资活动有关的现金0.0010,000.0020,000.00偿还债务支付的现金79,375.000.004,120.00分配股利.利润或利息支付的现金4,531.562,821.676,137.79筹
18、资活动产生的现金流量48,683.9711,178.3336,242.21汇率变动对现金的影响1.88-1.710.97现金及现金等价物净增加额35,256.51-6,209.41-22,320.23期初现金及现金等价物余额46,126.9481,383.4575,174.04期末现金及现金等价物余额81,383.4575,174.0452,853.822018 年,亚太药业的期末现金及现金等价物余额为 52,853.82 万元,其中,经营活动产生的现金流量是 3,699.48 万元,投资活动产生的现金流量是-62,262.89 万元,筹资活动产生的现金流量是 36,242.21 万元。现金及
19、现金等价物余额趋势81,383.4575,174.0452,853.822016年2017年2018年90,000.0080,000.0070,000.0060,000.0050,000.0040,000.0030,000.0020,000.0010,000.000.001.4所有者权益变动表表格4 2016-2018年度 所有者权益变动表项目(万元)2016 年2017 年2018 年Table 4 Changes in Owners Equity Sheets For 2016-2018上期期末余额79,315.42219,494.37236,927.21本期期初余额79,315.4221
20、9,494.37236,927.21本期增减变动金额140,178.9517,432.8415,488.22综合收益总额12,505.4120,115.3120,853.17利润分配-2,040.00-2,682.47-5,364.94对股东的分配-2,040.00-2,682.47-5,364.94期末余额219,494.37236,927.21252,415.43所有者权益期末余额变动趋势252,415.43236,927.21219,494.372016年2017年2018年260,000.00250,000.00240,000.00230,000.00220,000.00210,000
21、.00200,000.002会计报表分析2.1资产负债表分析2.1.1水平趋势分析表格5 2018年度 水平分析项目(万元)Table 5 Horizontal2017 年Analysis In 20182018 年变动额变动比影响总资产货币资金76,690.6653,449.99-23,240.67-30.30%-8.49%应收票据4,205.582,595.14-1,610.44-38.29%-0.59%应收账款27,403.9339,771.6412,367.7245.13%4.52%预付款项4,804.276,649.261,844.9938.40%0.67%其他应收款906.891,
22、063.20156.3117.24%0.06%存货11,535.2217,070.025,534.8047.98%2.02%其他流动资产980.604,108.453,127.85318.97%1.14%流动资产合计126,527.14124,707.70-1,819.44-1.44%-0.66%可供出售金融资产3,484.163,385.18-98.98-2.84%-0.04%固定资产22,241.1839,751.0517,509.8678.73%6.39%在建工程37,405.0444,834.517,429.4619.86%2.71%无形资产8,150.4110,314.372,163
23、.9626.55%0.79%开发支出500.009,812.819,312.811862.56%3.40%商誉67,039.4667,039.460.000.00%0.00%长期待摊费用5,715.767,658.671,942.9233.99%0.71%递延所得税资产463.20623.57160.3734.62%0.06%其他非流动资产2,280.0021,595.4019,315.40847.17%7.05%非流动资产合计147,279.21205,015.0257,735.8139.20%21.09%资产总计273,806.35329,722.7255,916.3720.42%20.4
24、2%短期借款4,000.007,500.003,500.0087.50%1.28%应付票据3,203.5310,464.617,261.08226.66%2.65%应付账款10,917.660.00-10,917.66-100.00%-3.99%预收款项1,588.131,002.74-585.39-36.86%-0.21%应付职工薪酬813.261,155.38342.1342.07%0.12%应交税费2,782.012,554.38-227.63-8.18%-0.08%应付利息5.320.00-5.32-100.00%0.00%其他应付款3,440.383,829.01388.6311.3
25、0%0.14%一年内到期的非流动负债0.002,420.002,420.000.00%0.88%流动负债合计26,750.2828,926.132,175.848.13%0.79%长期借款0.0016,460.0016,460.000.00%6.01%长期应付款10,005.0131,274.3221,269.31212.59%7.77%长期负债合计10,005.0147,734.3237,729.31377.10%13.78%递延所得税负债38.6523.80-14.85-38.42%-0.01%递延收益-非流动负债85.19623.04537.84631.32%0.20%非流动负债合计10
26、,128.8548,381.1638,252.30377.66%13.97%负债合计36,879.1477,307.2840,428.15109.62%14.77%实收资本(或股本)53,649.4553,649.450.000.00%0.00%资本公积130,695.62130,695.620.000.00%0.00%盈余公积4,997.576,055.951,058.3821.18%0.39%未分配利润46,339.9360,695.1814,355.2530.98%5.24%其他综合收益218.99134.87-84.13-38.42%-0.03%归属于母公司所有者权益合计235,901.56251,231.0615,329.506.50%5.60%少数股东权益1,025.651,184.37158.7215.47%0.06%所有者权益合计236,927.21252,415.4315,488.226.54%5.66%负债与所有者权益总计273,806.35329,722.7255,916.3720.42%20.42%从资产的角度对亚太药业